AlphaTON Capital to launch decentralized AI-native biotech platform

AlphaTON Capital (ATON) announced its intention to launch a decentralized, AI-native biotech platform focused on rare and immune-suppressed cancers, starting with mesothelioma. The planned platform is designed as a privacy-first decentralized-AI network for rare cancers that can learn across institutions without centralizing patient-sensitive data. In its initial phase, AlphaTON expects the platform to deliver practical, near-term outputs for mesothelioma, including biomarker and responder insights, enrichment strategies, and trial design simulations to help inform upcoming mesothelioma clinical trials at Cyncado Therapeutics, a wholly owned subsidiary of AlphaTON, alongside prioritization of repurposing candidates and novel combinations. Over time, the platform is intended to evolve into a continuous engine for therapeutic discovery and development, progressing toward new drug design. The platform will be trained initially on proprietary oncology datasets and program learnings from AlphaTON’s subsidiary Cyncado Therapeutics, providing a strong foundation and a meaningful head start in rare-cancer model development. AlphaTON plans to then expand the training base through additional proprietary datasets from partners, subject to appropriate permissions and governance. The initiative will be advanced through a dedicated platform entity that will seek independent third-party financing and non-dilutive funding at the platform level, while AlphaTON’s role will focus on infrastructure enablement, governance, and strategic alignment.